| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Cot inhibitor-1 targets the Cot/Tpl2 kinase (MAP3K8), a member of the MAP kinase kinase kinase family. Cot/Tpl2 is a key regulator of the ERK signaling pathway and plays a critical role in the production of pro-inflammatory cytokines, particularly TNF-alpha. By inhibiting Cot kinase activity, the compound reduces the production of TNF-alpha and other inflammatory mediators.
|
|---|---|
| ln Vitro |
In vitro, Cot inhibitor-1 inhibits TNF-alpha production in human whole blood with an IC50 of 5.7 nM. The compound demonstrates selective inhibition of Cot/Tpl2 kinase activity with an IC50 of 28 nM. These in vitro studies characterize the compound's potency and selectivity for its target kinase.
|
| ln Vivo |
In vivo activity data for Cot inhibitor-1 are suggested by its inhibition of TNF-alpha production in human whole blood. The compound may have potential therapeutic effects on inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and some types of cancer. Further in vivo studies are needed to confirm its efficacy in animal models of these diseases.
|
| Enzyme Assay |
In vitro kinase inhibition assays for Cot inhibitor-1 are performed using purified Cot/Tpl2 kinase enzyme. The kinase is incubated with a peptide substrate and ATP in the presence of increasing concentrations of the inhibitor. The extent of phosphorylation is measured using radiometric, fluorometric, or ELISA-based methods, and the IC50 (28 nM) is calculated from the inhibition curve. These cell-free assays provide quantitative data on the compound's potency.
|
| Cell Assay |
In vitro cellular assays for Cot inhibitor-1 are performed using human whole blood or immune cell lines. Cells are treated with the compound and stimulated to induce TNF-alpha production. TNF-alpha levels in the culture supernatant are measured by ELISA, and the IC50 for inhibition of TNF-alpha production (5.7 nM) is determined. These assays characterize the compound's anti-inflammatory activity.
|
| Animal Protocol |
In vivo animal experimental protocols for Cot inhibitor-1 are not extensively documented in the available literature. As a research compound with potential anti-inflammatory applications, in vivo studies would typically involve administration to animal models of inflammatory diseases such as rheumatoid arthritis or inflammatory bowel disease. Efficacy would be assessed by measuring disease severity and inflammatory markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cot inhibitor-1 have not been systematically characterized. The compound has a molecular weight of 553.46 and molecular formula C27H27Cl2FN8. It is soluble in DMSO at 25 mg/mL. The compound should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years. Further PK studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cot inhibitor-1 are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Cot inhibitor-1 (compound 28) is a selective Cot/Tpl2 (MAP3K8) kinase inhibitor with CAS number 915365-57-0, molecular formula C27H27Cl2FN8, and molecular weight 553.46. It has an IC50 of 28 nM against Cot/Tpl2 and inhibits TNF-alpha production in human whole blood with an IC50 of 5.7 nM. The compound has potential therapeutic applications in inflammatory diseases and cancer.
|
| Molecular Formula |
C27H27N8FCL2
|
|---|---|
| Molecular Weight |
553.46128
|
| Exact Mass |
552.172
|
| CAS # |
915365-57-0
|
| PubChem CID |
11584834
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.42g/cm3
|
| Boiling Point |
729.961ºC at 760 mmHg
|
| Flash Point |
395.267ºC
|
| Index of Refraction |
1.692
|
| LogP |
6.459
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
38
|
| Complexity |
792
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZWFKJFUFYPOTKL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H27Cl2FN8/c28-23-12-19(5-6-25(23)30)34-26-18(14-31)15-33-27-22(26)11-20(13-24(27)29)32-16-21-17-38(36-35-21)10-9-37-7-3-1-2-4-8-37/h5-6,11-13,15,17,32H,1-4,7-10,16H2,(H,33,34)
|
| Chemical Name |
6-[[1-[2-(azepan-1-yl)ethyl]triazol-4-yl]methylamino]-8-chloro-4-(3-chloro-4-fluoroanilino)quinoline-3-carbonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~45.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8068 mL | 9.0341 mL | 18.0682 mL | |
| 5 mM | 0.3614 mL | 1.8068 mL | 3.6136 mL | |
| 10 mM | 0.1807 mL | 0.9034 mL | 1.8068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
